Celldex Therapeutics (CLDX) Shares are Down -4.01%

Celldex Therapeutics (CLDX) : During the past 4 weeks, traders have been relatively bearish on Celldex Therapeutics (CLDX), hence the stock is down -28.02% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.49% relative to the S&P 500. The 4-week change in the price of the stock is -28.11% and the stock has fallen -4.01% in the past 1 week.

The stock has recorded a 20-day Moving Average of 16.43% and the 50-Day Moving Average is 22.94%.The 200 Day SMA reached 52.7%. Celldex Therapeutics, Inc. has dropped 31.07% during the last 3-month period . Year-to-Date the stock performance stands at -78.64%.


Celldex Therapeutics (NASDAQ:CLDX): The stock opened in the green at $3.35 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $3.38 and a low of $3.23 for the day. The stock did not find buyers even at the lows and closed at $3.35 recording a loss of -0.30%. 1,214,563 shares exchanged hands during the trading day. The stock had closed at $3.36 in the previous days trading.

Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.